치료용 알부민 시장

Growth Factors of therapeutic albumin Market

The global therapeutic albumin market is witnessing steady growth due to the increasing prevalence of chronic diseases, trauma, and burn injuries. Therapeutic albumin, a purified protein derived primarily from human blood plasma, plays a crucial role in maintaining oncotic pressure, transporting hormones, enzymes, and drugs, and treating hypovolemia, burns, hypoalbuminemia, acute liver failure, and shock. The market's expansion is further supported by advancements in recombinant albumin production and increasing applications in regenerative medicine and cell therapy.

In 2025, the market was valued at USD 7.23 billion, growing to USD 7.70 billion in 2026, and projected to reach USD 13.33 billion by 2034, registering a CAGR of 7.10% from 2026-2034. Asia Pacific dominated in 2025 with a 55.49% share, driven by a high incidence of chronic diseases and burn cases.

Market Drivers and Trends

Increasing Chronic Disease Burden and Burn Incidents

The rising prevalence of liver disorders, kidney diseases, and cancer, along with increasing burn injuries, is driving market growth. For instance, the U.S. had 6.0 million kidney disease cases and 4.5 million chronic liver disease cases in 2024, while 32,540 severe burn cases required hospitalization in 2023, highlighting the significant demand for therapeutic albumin in fluid resuscitation and critical care settings.

Advancements in Albumin Production

Due to limitations of human-derived albumin, such as supply shortages, pathogen transmission risk, and batch variability, companies are investing in recombinant albumin and advanced albumin formulations. Innovations like Shilpa Medicare's sRbumin, a yeast-derived recombinant albumin, address supply gaps and improve safety and consistency.

Emerging Applications in Regenerative Medicine

Therapeutic albumin's biocompatibility and protein stabilization properties make it ideal for cell therapy and tissue engineering, presenting new opportunities for market growth. Collaborations, such as Albumedix and Heartseed, are exploring recombinant albumin in cardiac cell therapy, indicating expanding clinical applications.

Market Challenges

Regulatory hurdles, high production costs, and limited availability of human plasma remain key challenges. Approval processes from the FDA, EMA, and NMPA slow product launches, while developing economies struggle with accessibility and affordability. Supply chain disruptions, such as the 2024 U.S. blood shortage reported by the American Red Cross, further constrain market growth.

Market Segmentation

By Source

• Human-derived albumin dominates with a 65.17% share in 2026, driven by chronic disease prevalence and robust product offerings from companies like Grifols, S.A., Octapharma AG, and Kedrion S.p.A.
• Other sources, including recombinant or plant-derived albumin, are gaining traction to overcome supply constraints.

By Indication

• Burns account for 89.66% of the market in 2026, due to fluid loss management in burn patients.
• Hypovolemia is growing steadily due to conditions like extreme perspiration, diarrhea, or chronic heart and kidney disease.
• Hypoalbuminemia and other indications exhibit moderate growth.

By Distribution Channel

• Hospital pharmacies dominate (54.56% in 2026) due to inpatient treatments and surgical procedures.
• Retail pharmacies provide widespread accessibility.
• Online pharmacies are growing rapidly, fueled by digital adoption and home delivery convenience.

Regional Insights

Asia Pacific dominated in 2025 with USD 4.01 billion, projected to lead with Japan at USD 0.85 billion, China at USD 1.86 billion, and India at USD 0.46 billion in 2026, driven by chronic disease prevalence and burn cases.

North America is growing steadily, with the U.S. market projected at USD 1.52 billion in 2026, benefiting from strong plasma donation networks and advanced manufacturing facilities.

Europe holds the second-largest market, with the UK at USD 0.18 billion and Germany at USD 0.28 billion in 2026, supported by clinical trials and research activities.

Latin America and the Middle East & Africa hold smaller shares but are expected to grow due to rising chronic disease prevalence and increasing plasma collection initiatives.

Competitive Landscape

Key players like Grifols, S.A., Octapharma AG, Kedrion S.p.A., Takeda Pharmaceutical, CSL, and China Biologic dominate the market through strategic acquisitions, collaborations, and new product launches. Notable developments include Grifols inaugurating a new purification plant in Dublin (2022) and Shilpa Medicare completing FDA inspection of its facility in India (2025), highlighting the focus on production capacity expansion and regulatory compliance.

Conclusion

The therapeutic albumin market is projected to grow from USD 7.23 billion in 2025 to USD 13.33 billion by 2034, driven by chronic disease prevalence, burn injuries, technological advancements in recombinant albumin, and expanding clinical applications in regenerative medicine. Asia Pacific remains the leading region, while North America and Europe continue steady growth. Challenges like supply constraints, regulatory barriers, and high production costs persist, but innovations in recombinant albumin and advanced formulations are expected to sustain market growth and improve global patient access to this vital therapeutic protein.

Segmentation By Source

• Human
• Others

By Indication

• Hypovolemia
• Hypoalbuminemia
• Burn
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region

• North America (By Source, Indication, Distribution Channel, and Country)
  • U.S.
  • Canada
• Europe (By Source, Indication, Distribution Channel, and Country/Sub-region)
  • U.K.
  • Germany
  • France
  • Italy
  • Spain
  • Scandinavia
  • Rest of Europe
• Asia Pacific (By Source, Indication, Distribution Channel, and Country/Sub-region)
  • Japan
  • China
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America (By Source, Indication, Distribution Channel, and Country/Sub-region)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (By Source, Indication, Distribution Channel, and Country/Sub-region)
  • GCC
  • South Africa
  • Rest of the Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Prevalence of Key Disorders: by Key Countries/Sub-regions, 2025
• 4.2. Overview: rHSA Product Parameters
• 4.3. New Product Launches, By Key Players
• 4.4. Pipeline Analysis, By Key Players
• 4.5. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
• 4.6. Impact of COVID-19 on the Global Therapeutic Albumin Market

5. Global Therapeutic Albumin Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Source
  • 5.1.1. Human
  • 5.1.2. Others
• 5.2. Market Analysis, Insights and Forecast - By Indication
  • 5.2.1. Hypovolemia
  • 5.2.2. Hypoalbuminemia
  • 5.2.3. Burn
  • 5.2.4. Others
• 5.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 5.3.1. Hospital Pharmacies
  • 5.3.2. Retail Pharmacies
  • 5.3.3. Online Pharmacies
• 5.4. Market Analysis, Insights and Forecast - Region
  • 5.4.1. North America
  • 5.4.2. Europe
  • 5.4.3. Asia Pacific
  • 5.4.4. Latin America
  • 5.4.5. Middle East & Africa

6. North America Therapeutic Albumin Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Source
  • 6.1.1. Human
  • 6.1.2. Others
• 6.2. Market Analysis, Insights and Forecast - By Indication
  • 6.2.1. Hypovolemia
  • 6.2.2. Hypoalbuminemia
  • 6.2.3. Burn
  • 6.2.4. Others
• 6.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 6.3.1. Hospital Pharmacies
  • 6.3.2. Retail Pharmacies
  • 6.3.3. Online Pharmacies
• 6.4. Market Analysis, Insights and Forecast - By Country
  • 6.4.1. U.S.
  • 6.4.2. Canada

7. Europe Therapeutic Albumin Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Source
  • 7.1.1. Human
  • 7.1.2. Others
• 7.2. Market Analysis, Insights and Forecast - By Indication
  • 7.2.1. Hypovolemia
  • 7.2.2. Hypoalbuminemia
  • 7.2.3. Burn
  • 7.2.4. Others
• 7.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 7.3.1. Hospital Pharmacies
  • 7.3.2. Retail Pharmacies
  • 7.3.3. Online Pharmacies
• 7.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 7.4.1. Germany
  • 7.4.2. U.K.
  • 7.4.3. France
  • 7.4.4. Italy
  • 7.4.5. Spain
  • 7.4.6. Scandinavia
  • 7.4.7. Rest of Europe

8. Asia Pacific Therapeutic Albumin Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Source
  • 8.1.1. Human
  • 8.1.2. Others
• 8.2. Market Analysis, Insights and Forecast - By Indication
  • 8.2.1. Hypovolemia
  • 8.2.2. Hypoalbuminemia
  • 8.2.3. Burn
  • 8.2.4. Others
• 8.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 8.3.1. Hospital Pharmacies
  • 8.3.2. Retail Pharmacies
  • 8.3.3. Online Pharmacies
• 8.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 8.4.1. China
  • 8.4.2. Japan
  • 8.4.3. India
  • 8.4.4. Australia
  • 8.4.5. Southeast Asia
  • 8.4.6. Rest of Asia Pacific

9. Latin America Therapeutic Albumin Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Source
  • 9.1.1. Human
  • 9.1.2. Others
• 9.2. Market Analysis, Insights and Forecast - By Indication
  • 9.2.1. Hypovolemia
  • 9.2.2. Hypoalbuminemia
  • 9.2.3. Burn
  • 9.2.4. Others
• 9.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 9.3.1. Hospital Pharmacies
  • 9.3.2. Retail Pharmacies
  • 9.3.3. Online Pharmacies
• 9.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 9.4.1. Brazil
  • 9.4.2. Mexico
  • 9.4.3. Rest of Latin America

10. Middle East & Africa Therapeutic Albumin Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Source
  • 10.1.1. Human
  • 10.1.2. Others
• 10.2. Market Analysis, Insights and Forecast - By Indication
  • 10.2.1. Hypovolemia
  • 10.2.2. Hypoalbuminemia
  • 10.2.3. Burn
  • 10.2.4. Others
• 10.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 10.3.1. Hospital Pharmacies
  • 10.3.2. Retail Pharmacies
  • 10.3.3. Online Pharmacies
• 10.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 10.4.1. GCC
  • 10.4.2. South Africa
  • 10.4.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles
  • 11.2.1. Takeda Pharmaceutical Company Limited.
    • 11.2.1.1. Overview
    • 11.2.1.2. Products
    • 11.2.1.3. SWOT Analysis
    • 11.2.1.4. Recent Developments
    • 11.2.1.5. Strategies
    • 11.2.1.6. Financials (Based on Availability)
  • 11.2.2. CSL
    • 11.2.2.1. Overview
    • 11.2.2.2. Products
    • 11.2.2.3. SWOT Analysis
    • 11.2.2.4. Recent Developments
    • 11.2.2.5. Strategies
    • 11.2.2.6. Financials (Based on Availability)
  • 11.2.3. Grifols, S.A.
    • 11.2.3.1. Overview
    • 11.2.3.2. Products
    • 11.2.3.3. SWOT Analysis
    • 11.2.3.4. Recent Developments
    • 11.2.3.5. Strategies
    • 11.2.3.6. Financials (Based on Availability)
  • 11.2.4. Octapharma AG
    • 11.2.4.1. Overview
    • 11.2.4.2. Products
    • 11.2.4.3. SWOT Analysis
    • 11.2.4.4. Recent Developments
    • 11.2.4.5. Strategies
    • 11.2.4.6. Financials (Based on Availability)
  • 11.2.5. Kedrion S.p.A.
    • 11.2.5.1. Overview
    • 11.2.5.2. Products
    • 11.2.5.3. SWOT Analysis
    • 11.2.5.4. Recent Developments
    • 11.2.5.5. Strategies
    • 11.2.5.6. Financials (Based on Availability)
  • 11.2.6. Biotest AG
    • 11.2.6.1. Overview
    • 11.2.6.2. Products
    • 11.2.6.3. SWOT Analysis
    • 11.2.6.4. Recent Developments
    • 11.2.6.5. Strategies
    • 11.2.6.6. Financials (Based on Availability)
  • 11.2.7. LFB (France)
    • 11.2.7.1. Overview
    • 11.2.7.2. Products
    • 11.2.7.3. SWOT Analysis
    • 11.2.7.4. Recent Developments
    • 11.2.7.5. Strategies
    • 11.2.7.6. Financials (Based on Availability)
  • 11.2.8. China Biologic Products Holdings, Inc.
    • 11.2.8.1. Overview
    • 11.2.8.2. Products
    • 11.2.8.3. SWOT Analysis
    • 11.2.8.4. Recent Developments
    • 11.2.8.5. Strategies
    • 11.2.8.6. Financials (Based on Availability)
  • 11.2.9. Baxter
    • 11.2.9.1. Overview
    • 11.2.9.2. Products
    • 11.2.9.3. SWOT Analysis
    • 11.2.9.4. Recent Developments
    • 11.2.9.5. Strategies
    • 11.2.9.6. Financials (Based on Availability)